Clinical Research
Site selection is where clinical programs succeed or fail in practice. Choosing investigators with the right patient population, infrastructure, and regulatory experience — and managing them effectively through enrollment — is a distinct operational discipline that determines whether a trial delivers clean, submission-ready data.
Build Your Site NetworkSite Operations
The most common site selection mistake is optimizing for investigator enthusiasm and ignoring operational readiness. An investigator who is genuinely excited about the device but whose site lacks qualified study coordinators, appropriate patient volume, reliable IRB turnaround, and the infrastructure to maintain study records correctly is a liability, not an asset. We evaluate sites against a structured qualification matrix that covers patient access, staff experience with FDA-regulated device studies, device handling and storage capabilities, IRB relationship, and prior FDA inspection history where available.
Under 21 CFR Part 812, sponsors are responsible for selecting qualified investigators — meaning investigators with the training and experience necessary to conduct the investigation and sufficient resources to do so. That responsibility includes site qualification documentation. A site qualification visit report is not bureaucratic overhead; it is your documentation that you discharged the regulatory obligation to select qualified investigators. FDA investigators inspect this documentation during sponsor audits.
Site initiation visits (SIVs) are the moment at which a site transitions from qualified to operational. A properly executed SIV ensures that the principal investigator and all delegated study staff have received protocol-specific training documented in the delegation log, that site regulatory files (the Investigator Site File) are complete and organized, that device accountability procedures are in place, and that the site's IRB approval and applicable regulations are current before enrollment begins.
Common initiation failures include delegation logs that don't match actual staff responsibilities, inadequate protocol training documentation for high-turnover study coordinators, and incomplete regulatory binders that will fail an FDA sponsor inspection. We run SIVs to a structured agenda and close every initiation with a gap list reviewed with the PI before the visit concludes.
Post-initiation monitoring under 21 CFR Part 812.46 requires sponsors to monitor investigations to ensure compliance with the approved protocol. In practice, monitoring involves periodic source data verification (SDV) visits or remote chart access reviews, protocol deviation detection and reporting, device accountability reconciliation, and enrollment tracking against projections.
Protocol deviations that are not identified, documented, and corrected promptly accumulate into patterns that FDA and data safety monitoring boards use to assess site performance. Unaddressed deviation patterns can require site suspension, data exclusion, or, in serious cases, trigger an IDE audit. Our monitoring programs are risk-stratified: higher-risk procedures and higher-volume sites receive more frequent and intensive oversight, with remote monitoring filling intervals between onsite visits.
Get Started
The difference between a trial that produces clean FDA submission data and one that doesn't is almost always site selection and monitoring discipline. We build site programs designed to close with the data quality your submission requires.